Curis (NASDAQ:CRIS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Curis (NASDAQ:CRIS) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock.

Curis Price Performance

CRIS opened at $3.80 on Friday. The business’s 50-day moving average price is $5.01 and its two-hundred day moving average price is $7.00. Curis has a 1 year low of $3.51 and a 1 year high of $17.49. The company has a market capitalization of $22.72 million, a price-to-earnings ratio of -0.51 and a beta of 3.35.

Hedge Funds Weigh In On Curis

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after acquiring an additional 10,097 shares in the last quarter. Focused Wealth Management Inc grew its holdings in shares of Curis by 63.1% in the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 20,908 shares in the last quarter. CM Management LLC grew its holdings in shares of Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Curis by 795.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 96,256 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.